Risk factors | Frequency (%) or Mean value ± SD | Univariate analysis | ||
---|---|---|---|---|
VRE Colonized (n = 22) | VRE non-Colonized (n = 69) | OR (95% CI) | p-value | |
Demographics | ||||
Age (years) | 62.5 ± 14.83 | 57.36 ± 16.59 | 1.670 (0.631–4.418) | 0.299 |
Gender; male: female | 7:15 | 20:49 | 0.875 (0.310–2.467) | 0.800 |
Mean length of stay (days) | 16.86 (3–55) | 14 (3-105) | 1.560 (0.594–4.094) | 0.365 |
Reason for admission in ICU; n (%) | ||||
Septic shock | 2 (9.1) | 5 (7.3) | 1.28 (0.23–7.11) | 0.247 |
Postoperative critical cares | 8 (36.4) | 55 (79.7) | 0.145 (0.051–0.415) | < 0.001 |
Respiratory failure | 3 (13.6) | 3 (4.3) | 3.474 (0.648–18.632) | 0.150 |
Trauma | 2 (9.1) | 2 (2.9) | 3.350 (0.443–25.319) | 0.245 |
Others* | 7 (31.8) | 4 (5.8) | 7.583 (1.965–29.272) | 0.003 |
Underling diseases; n (%) | ||||
Cardiovascular | 16 (72.7) | 28 (40.6) | 3.905 (1.361–11.205) | 0.009 |
Respiratory | 2 (9.1) | 5 (7.2) | 1.280 (0.230–7.112) | 0.674 |
Hepatobiliary | 1 (4.5) | 4 (5.8) | 0.774 (0.082–7.311) | 0.651 |
Gastrointestinal | 1 (4.5) | 3 (4.3) | 1.048 (0.103–10.616) | 0.969 |
Genitourinary | 1 (4.5) | 3 (4.3) | 1.048 (0.103–10.616) | 0.969 |
Endocrine | 5 (22.7) | 14 (20.3) | 1.155 (0.363–3.675) | 0.772 |
Malignancies | 1 (4.5) | 8 (11.6) | 0.363 (0.043–3.077) | 0.446 |
Recent abdominal operations | 5 (22.7) | 21 (30.4) | 0.672 (0.219–2.063) | 0.486 |
Use of invasive devices; n (%) | ||||
Central venous catheter | 21 (95.5) | 57 (82.6) | 4.421 (0.541–36.119) | 0.176 |
Drainage tube | 16 (72.7) | 57 (82.6) | 0.561 (0.182–1.731) | 0.360 |
Nasogastric tube | 4 (18.2) | 17 (24.6) | 0.680 (0.202–2.288) | 0.531 |
Urinary catheter | 12 (54.5) | 42 (60.9) | 0.771 (0.293–2.032) | 0.599 |
Endotracheal tube | 15 (68.2) | 65 (94.2) | 0.132 (0.034–0.509) | 0.003 |
Antibiotic use during the current hospital stay; n (%) | ||||
Penicillins | 1 (4.5) | 4 (5.8) | 0.774 (0.082–7.311) | 0.822 |
1st generation cephalosporins | 1 (4.5) | 1 (1.4) | 3.238 (0.194–54.036) | 0.427 |
3rd generation cephalosporins | 13 (65) | 54(76.1) | 0.585 (0.201–1.702) | 0.322 |
4rd generation cephalosporins | 1 (4.5) | 1 (1.4) | 3.238 (0.194–54.036) | 0.427 |
Carbapenems | 3 (13.6) | 4 (5.8) | 2.566 (0.528–12.479) | 0.353 |
Aminoglycosides | - | 7 (10.1) | 0.19 (0.01–3.38) | 0.189 |
Metronidazole | 7 (31.8) | 31 (44.9) | 0.572 (0.207–1.578) | 0.278 |
Fluoroquinolones | 1 (4.5) | 3 (4.3) | 1.048 (0.103–10.616) | 0.969 |
Tigecycline | - | 3 (4.3) | 0.42 (0.02–8.49) | 0.610 |
Vancomycin | 1 (4.5) | 3 (4.3) | 1.048 (0.103–10.616) | 0.969 |
Antifungal drugs | 5 (22.7) | 10 (14.5) | 1.735 (0.522–5.770) | 0.509 |
Colistin | 2 (9.1) | 2 (2.9) | 3.350 (0.443–25.319) | 0.245 |
Clindamycin | 1 (4.5) | 2 (2.9) | 1.595 (1.138–18.486) | 0.569 |
Linezolid | - | 3 (4.3) | 0.42 (0.02–8.49) | 0.320 |